Lipid disorders with concomitant hyperuricemia – the scale of the problem and the benefits of fenofibrate Review article
Article Sidebar
Published:
Dec 1, 2024
Keywords:
fenofibrate, hypertriglyceridemia, hyperuricemia
Main Article Content
Abstract
The classic role of fenofibrate in the treatment of hyperlipidemia, especially the lowering of pro-atherogenic fractions, is discussed. However, its role in the treatment of other concomitant metabolic disorders, including metabolic syndrome, diabetes and hyperuricemia, has been emphasized. Pleiotropic effects of the drug have been described to explain the reduction of adverse cardiovascular events in patients treated with fenofibrate. The drug works well in combination therapy, is well tolerated, and the function of the kidneys and liver should be monitored periodically.
Article Details
How to Cite
Sapilak, B. J. (2024). Lipid disorders with concomitant hyperuricemia – the scale of the problem and the benefits of fenofibrate. Medycyna Faktow (J EBM), 17(3(64), 349-354. https://doi.org/10.24292/01.MF.0324.05
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Szymański M, Barylski M, Cybulska B et al. Rekomendacje dotyczące leczenia dyslipidemii w Polsce — III Deklaracja Sopocka Interdyscyplinarne stanowisko grupy ekspertów wsparte przez Sekcję Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Choroby Serca i Naczyń. 2018; 15(4): 199-210.
2. Mark L, Vallejo-Vaz AJ, Reiber I et al. Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: A nationwide survey of 2674 individuals in Hungary. Atherosclerosis. 2015; 241(1): 62-8.
3. Zhao S, Wang F, Dai Y et al. Efficacy and safety of fenofibrate as an add-on in patients with elevated triglyceride despite receiving statin treatment. Int J Cardiol. 2016; 221: 832-6.
4. Shinnakasu A, Yamamoto K, Kurano M et al. The Combination Therapy of Fenofibrate and Ezetimibe Improved Lipid Profile and Vascular Function Compared with Statins in Patients with Type 2 Diabetes. J Atheroscler Thromb. 2017; 24(7): 735-48.
5. Alperovitch A, Kurth T, Bertrand M et al. Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: population based cohort study. BMJ. 2015; 350: h2335.
6. Rajca A, Wojciechowska A, Śmigielski W et al. Increase in the prevalence of metabolic syndrome in Poland: comparison of the results of the WOBASZ (2003-2005) and WOBASZ II (2013-2014) studies. Pol Arch Intern Med. 2021; 131(6): 520-6.
7. Fang Y, Mei W, Wang C et al. Dyslipidemia and hyperuricemia: a cross-sectional study of residents in Wuhu, China. BMC Endocr Disord. 2024; 24(1): 2.
8. Hou YL, Yang XL, Wang CX et al. Hypertriglyceridemia and hyperuricemia: a retrospective study of urban residents. Lipids Health Dis. 2019; 18(1): 81.
9. Widecka K, Szymański FM, Filipiak KJ et al. Stanowisko ekspertów dotyczące hyperurykemii i jej leczenia u pacjentów z wysokim ryzykiem sercowo-naczyniowym. Arterial Hypertens. 2017; 21(1): 1-9.
10. Uetake D, Ohno I, Ichida K et al. Effect of fenofibrate on uric acid metabolism and urate transporter 1. Intern Med. 2010; 49(2): 89-94.
11. Winder M, Chudek J. Częstość występowania oraz czynniki wywołujące hyperurykemię u osób w wieku podeszłym. Gerontologia Polska. 2020; 28: 38-44.
12. McQuillan GM, McLean JE, Chiappa M et al. National Health and Nutrition Examination Survey Biospecimen Program: NHANES III (1988-1994) and NHANES 1999-2014. Vital Health Stat 2. 2015; (170): 1-14.
13. Borghi C, Tykarski A, Widecka K et al. Konsensus ekspertów dotyczący diagnozowania i leczenia pacjentów z hyperurykemią oraz wysokim ryzykiem sercowo-naczyniowym. Varia Medica. 2018; 2(6): 495-515.
14. Norvik JV, Storhaug HM, Ytrehus K et al. Overweight modifies the longitudinal association between uric acid and some components of the metabolic syndrome: The Tromso Study. BMC Cardiovasc Disord. 2016; 16: 85.
15. Waldman B, Ansquer JC, Sullivan DR et al.; FIELD investigators. Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. Lancet Diabetes Endocrinol. 2018; 6(4): 310-8.
16. Feher MD, Hepburn AL, Hogarth MB et al. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology. 2003; 2(42): 321-5.
17. Sun X, Liu J, Wang G. Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia. Lipids Health Dis. 2020; 19(1): 103.
2. Mark L, Vallejo-Vaz AJ, Reiber I et al. Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: A nationwide survey of 2674 individuals in Hungary. Atherosclerosis. 2015; 241(1): 62-8.
3. Zhao S, Wang F, Dai Y et al. Efficacy and safety of fenofibrate as an add-on in patients with elevated triglyceride despite receiving statin treatment. Int J Cardiol. 2016; 221: 832-6.
4. Shinnakasu A, Yamamoto K, Kurano M et al. The Combination Therapy of Fenofibrate and Ezetimibe Improved Lipid Profile and Vascular Function Compared with Statins in Patients with Type 2 Diabetes. J Atheroscler Thromb. 2017; 24(7): 735-48.
5. Alperovitch A, Kurth T, Bertrand M et al. Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: population based cohort study. BMJ. 2015; 350: h2335.
6. Rajca A, Wojciechowska A, Śmigielski W et al. Increase in the prevalence of metabolic syndrome in Poland: comparison of the results of the WOBASZ (2003-2005) and WOBASZ II (2013-2014) studies. Pol Arch Intern Med. 2021; 131(6): 520-6.
7. Fang Y, Mei W, Wang C et al. Dyslipidemia and hyperuricemia: a cross-sectional study of residents in Wuhu, China. BMC Endocr Disord. 2024; 24(1): 2.
8. Hou YL, Yang XL, Wang CX et al. Hypertriglyceridemia and hyperuricemia: a retrospective study of urban residents. Lipids Health Dis. 2019; 18(1): 81.
9. Widecka K, Szymański FM, Filipiak KJ et al. Stanowisko ekspertów dotyczące hyperurykemii i jej leczenia u pacjentów z wysokim ryzykiem sercowo-naczyniowym. Arterial Hypertens. 2017; 21(1): 1-9.
10. Uetake D, Ohno I, Ichida K et al. Effect of fenofibrate on uric acid metabolism and urate transporter 1. Intern Med. 2010; 49(2): 89-94.
11. Winder M, Chudek J. Częstość występowania oraz czynniki wywołujące hyperurykemię u osób w wieku podeszłym. Gerontologia Polska. 2020; 28: 38-44.
12. McQuillan GM, McLean JE, Chiappa M et al. National Health and Nutrition Examination Survey Biospecimen Program: NHANES III (1988-1994) and NHANES 1999-2014. Vital Health Stat 2. 2015; (170): 1-14.
13. Borghi C, Tykarski A, Widecka K et al. Konsensus ekspertów dotyczący diagnozowania i leczenia pacjentów z hyperurykemią oraz wysokim ryzykiem sercowo-naczyniowym. Varia Medica. 2018; 2(6): 495-515.
14. Norvik JV, Storhaug HM, Ytrehus K et al. Overweight modifies the longitudinal association between uric acid and some components of the metabolic syndrome: The Tromso Study. BMC Cardiovasc Disord. 2016; 16: 85.
15. Waldman B, Ansquer JC, Sullivan DR et al.; FIELD investigators. Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. Lancet Diabetes Endocrinol. 2018; 6(4): 310-8.
16. Feher MD, Hepburn AL, Hogarth MB et al. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology. 2003; 2(42): 321-5.
17. Sun X, Liu J, Wang G. Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia. Lipids Health Dis. 2020; 19(1): 103.